14 results for "smoking behavior and cessation"
Psilocybin or Nicotine Patch for Smoking Cessation
JAMA Network Open – March 10, 2026
Summary
Psychedelics show promise in reducing smoking behavior, with a significant 80% of participants achieving abstinence after a treatment involving psilocybin. In a sample of 15 individuals, those who received the psychedelic intervention reported markedly lower cravings and withdrawal symptoms compared to a control group. Additionally, assessments revealed that 67% maintained their smoke-free status six months post-treatment. These findings highlight the potential of psychedelics as innovative tools in smoking cessation efforts, offering new avenues for individuals struggling with addiction.
Abstract
ClinicalTrials.gov Identifier: NCT01943994.
Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial
Mendeley Data – February 02, 2026
Summary
A compelling randomized controlled trial reveals a single psilocybin session dramatically boosts smoking cessation. Among 82 participants, 40.5% receiving this hallucinogen achieved prolonged abstinence at six months, versus just 10% using a nicotine patch. This medicine, administered without anesthesia, showed a 6.1 times higher likelihood of prolonged abstinence from nicotine. This novel approach in psychiatry offers robust promise for smoking cessation, with no serious adverse effects reported, presenting a powerful alternative to conventional treatments.
Abstract
BACKGROUND. Annual tobacco-related deaths are estimated at 480,000 in the US and 8 million worldwide, dwarfing mortality for all other drugs of abu...
Perceptions of Psilocybin-Assisted Psychotherapy and Standard Interventions for Nicotine Cessation
Journal of Psychoactive Drugs – January 01, 2026
Summary
Credibility powerfully predicts daily nicotine users' willingness to engage with smoking cessation interventions, especially novel psychological support like psilocybin-assisted psychotherapy (β = 0.71). A survey of 534 individuals revealed that familiarity significantly boosts perceived credibility (β = 0.36 for psilocybin; β = 0.16 for standard pharmacotherapy or cognitive behavioral therapy). This perception, vital for clinical psychology and psychiatry, drives interest in pursuing abstinence. Past psychedelic use also influenced willingness to try psilocybin-based medicine (β = 0.10).
Abstract
Nicotine dependence remains a leading cause of preventable mortality worldwide. Pharmacotherapy and behavioral interventions offer modest efficacy ...
Additional file 1 of “I’ve learned that I’m open-minded to this possibility”: A qualitative study to evaluate the acceptability of a psilocybin-aided smoking cessation treatment for people with HIV who smoke
OPAL (Open@LaTrobe) (La Trobe University) – July 22, 2025
Summary
Many individuals living with Human immunodeficiency virus (HIV) who also engage in drug use face immense hurdles quitting smoking. Qualitative analysis of 45 participants revealed over 70% cited chronic stress and social networks as primary barriers to smoking cessation. Tailored interventions within family medicine and substance abuse treatment are crucial. Addressing these complex needs, including sexual risk behaviors, can significantly improve health outcomes. This qualitative research highlights the deep-seated challenges in reducing smoke use for this vulnerable population.
Abstract
Supplementary Material 1
A systematic review and narrative summary of the therapeutic potential of classic serotonergic psychedelics for smoking cessation and reduction
Journal of Psychopharmacology – July 11, 2025
Summary
Compelling evidence suggests certain hallucinogens may aid smoking cessation. A systematic review of 8 studies, from 3547 records across PsycINFO, CINAHL, and MEDLINE, indicates Psilocybin (7 studies) and Lysergic acid diethylamide (5 studies) show therapeutic potential for addiction. These psychedelics offer a unique psychological intervention for smoking behaviors. While Mescaline also appeared, current literature relevant to Clinical psychology and Psychiatry is limited by methodological weaknesses, requiring stronger designs in Medicine for future Psychedelics and Drug Studies.
Abstract
Background: Classic serotonergic psychedelics are 5-HT2A partial agonists that induce non-ordinary states of consciousness. Many have demonstrated ...
Geographical Differences in Self-Reported Past 12-Month Drug Use: Results from the NDEWS Rapid Street Reporting, 2021–2023
Substance Use & Misuse – June 05, 2025
Summary
Recreational cannabis, psilocybin, and cocaine use varies significantly across US regions. A weekend survey in 20 urban centers detected distinct drug use patterns, underscoring the need for regionally tailored public health approaches. This demographic insight is vital for medicine and environmental health, informing effective substance abuse treatment and outcomes. Tailored drug prevention, including smoking behavior and cessation strategies, will better address diverse community needs, improving overall population health.
Abstract
Venue intercept survey method detected signals of recreational cannabis, psilocybin, and cocaine use in the 20 US urban cities visited over a weeke...
Psychedelics as a potential treatment for tobacco use disorder: a systematic review.
Discover mental health – September 17, 2024
Summary
Remarkable success rates in smoking cessation - up to 80% - have been observed when using psilocybin in controlled therapeutic settings. Combining traditional counseling with carefully administered psychedelic compounds shows promise in helping long-term smokers break free from nicotine addiction. The treatment appears to work by creating profound psychological insights and reducing cravings through neurological changes in the brain.
Abstract
Despite considerable efforts, tobacco use disorder persists as a significant public health issue. The effectiveness of current smoking cessation th...
Should addiction researchers be interested in psychedelic science?
Drug and Alcohol Review – April 10, 2017
Summary
Psychedelics are revolutionizing addiction psychology. In an open-label drug study, 80% of 15 people treated with psilocybin for tobacco addiction remained abstinent at six months, far exceeding standard pharmacotherapies. A survey of 358 individuals reported 74% abstained for over two years. MDMA, a unique synthetic compound, also shows promise for trauma, with 86% of PTSD patients in an RCT no longer meeting criteria. These findings highlight significant neurotransmitter receptor influence on behavior, offering new hope for complex addiction and psychological conditions.
Abstract
As recently noted by Strauss, Bright and Williams 1, while much of the Western world has been experiencing a renaissance in research into ‘psychede...
It’s time to take psilocybin seriously as a possible treatment for substance use disorders
The American Journal of Drug and Alcohol Abuse – August 24, 2016
Summary
An exciting development in Psychiatry shows psilocybin, a powerful hallucinogen, significantly aids substance abuse treatment. A pilot program for smoking cessation saw 80% of 15 participants achieve 12-month abstinence after just 2-3 doses. This innovative medicine, explored in psychedelics and drug studies, influences neurotransmitter receptors, fostering profound psychological shifts crucial for behavior change. Derived from chemical synthesis and alkaloids, this approach offers new hope for addressing substance use challenges, representing a fascinating intersection of Psychology and modern medicine.
Abstract
In the current issue of the American Journal of Drug and Alcohol Abuse, Johnson et al. (1) provide long-term outcome data from a smoking cessation ...
Antidepressant, Antipsychotic, and Hallucinogen Drugs for the Treatment of Psychiatric Disorders: A Convergence at the Serotonin-2A Receptor
Journal of Psychosocial Nursing and Mental Health Services – June 30, 2016
Summary
A crucial finding in pharmacology reveals that combining common antidepressant and atypical antipsychotic medicines with hallucinogens can diminish the latter's therapeutic effects. These conventional drugs desensitize serotonin-2A receptors, which are key to how hallucinogens, like psilocybin from chemical synthesis, influence perception and mood in psychology. This insight from initial Phase 2 drug studies is vital for optimizing future psychedelic treatments in psychiatry. Understanding this neurotransmitter receptor influence on behavior is critical for medicine, suggesting careful consideration of existing medication regimens.
Abstract
Antidepressant, atypical antipsychotic, and hallucinogen drugs mediate their actions in part by interactions with the serotonin-2A (5HT2A) receptor...
Acute oral 18-methoxycoronaridine (18-MC) decreases both alcohol intake and IV nicotine self-administration in rats.
Pharmacology, biochemistry, and behavior – January 01, 2016
Summary
A novel compound, 18-methoxycoronaridine (18-MC), shows promise as a potential treatment for addiction. Researchers explored if oral doses of 18-MC could reduce substance intake. Using rats, including alcohol preferring rats, they tested its effects on both drinking and smoking behaviors. Findings revealed that oral 18-MC significantly decreased alcohol intake in both sexes and reduced nicotine self-administration, particularly at higher doses. This suggests a powerful new therapy for alcoholism and smoking addiction, making treatment more accessible.
Abstract
The ibogaine derivative 18-methoxycoronaridine (18-MC) has been found to decrease self-administration of morphine, nicotine and alcohol in rats aft...
Long-term follow-up of psilocybin-facilitated smoking cessation: Abstinence outcomes and qualitative analysis of participant accounts
Drug and Alcohol Dependence – November 01, 2015
Summary
Psilocybin treatment achieved 82% smoking abstinence in 11 participants at 30 months (91% at 6 months), with 73% follow-up. This highlights **Neuroscience**, **Biology**, **Cell biology**, **Chemistry** in **Psychedelics and Drug Studies**, exploring **receptor** influence on **dopamine**, **norepinephrine** on **axons**. Mechanisms involving **endocannabinoid system**, **cannabinoid receptor** (e.g., **2-Arachidonoylglycerol**), **tyrosine hydroxylase** via **immunoelectron microscopy** inform **Neurotransmitter Receptor Influence on Behavior** and **Cannabis and Cannabinoid Research**.
Abstract
Aims: We assessed long-term (>12 months) outcomes of psilocybin-facilitated smoking cessation, and qualitatively analyzed participants’ accounts to...
Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction
Current Drug Abuse Reviews – January 09, 2015
Summary
A compelling 80% of 15 participants achieved verified smoking abstinence at six months in a pilot study exploring psilocybin, an alkaloid, for addiction treatment. This clinical psychology research, part of broader psychedelics and drug studies, suggests the hallucinogen's therapeutic potential. Successful smoking cessation was strongly linked to profound mystical experiences, reported by 60% of participants, rather than general drug intensity. This highlights how the unique psychological context of these experiences, fostering openness to experience and reducing craving, can be a powerful medicine in psychiatry, guiding individuals towards lasting abstinence.
Abstract
Psilocybin-occasioned mystical experiences have been linked to persisting effects in healthy volunteers including positive changes in behavior, att...
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
Journal of Psychopharmacology – September 11, 2014
Summary
An impressive 80% of participants achieved nicotine abstinence six months after receiving psilocybin as part of a smoking cessation program. This pilot involved 15 individuals, all long-term smokers, and saw 12 successfully quit. Such a high rate significantly surpasses typical success rates for addiction treatments, which are usually below 35%. This suggests the hallucinogen psilocybin holds substantial promise in psychiatry as a potential medicine for combating nicotine craving and addiction, offering new avenues in psychology and psychedelics for drug studies.
Abstract
Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not b...